Today we are pleased to announce the closing of a Series E financing round worth $20 million. We are equally pleased to announce that Myriad Genetics has joined as a new strategic equity investor, joining our existing investors (including Mohr Davidow Ventures, Quaker BioVentures, All
Myriad Genetics joins existing venture investor syndicate to support RainDance’s growth as a leading provider of genetic research technologies LEXINGTON, Mass – April 29, 2013 – RainDance Technologies, Inc., the Digital Biology™ Company, today announced the closing of a $20 million Se
It’s a holiday reserved for die-hard science geeks: DNA Day, April 25th, celebrates the anniversaries of both Watson and Crick’s famous report on the double-helix structure of DNA and the completion of the Human Genome Project (HGP). It’s hard to believe that it has already been a dec
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.